Shenzhen Herz Life Science Technology Co., Ltd.

was founded by returned scientists from Germany and Switzerland. The company has developed multiple vaccines using a unique new vaccine technology platform, which have the characteristics of high safety, high immunogenicity, and high biological activity. The product can not only be applied to the prevention of infectious diseases, but also to the field of non communicable diseases, such as chronic disease treatment, cancer treatment, etc. The company's research and development capabilities have been highly recognized by peers and upstream and downstream enterprises. In the early stages of its establishment, it was favored by well-known investment institutions such as Qianhai Venture Capital and Qinzhi Capital.